StockMarketWire.com - Specialist drug developer ImmuPharma said its shares would be admitted to trading on Euronext Growth Brussels, effective 19 December.

The company, also listed on AIM, said the the dual listing aimed to further increase the visibility of its shares in continental Europe, where it was conducting its R&D activities in France and Switzerland.

It would also allow the company to join the top European exchange for life sciences and the world's second biggest for biotech companies outside the US, it added.




Story provided by StockMarketWire.com